| Schedule of continued operations by reportable segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
($in thousands)
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
|
|
Products
|
|
Product
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net revenue
|
|
$
|
11,946
|
|
$
|
972
|
|
$
|
12,918
|
|
Direct cost of goods
|
|
|
(3,810)
|
|
|
—
|
|
|
(3,810)
|
|
Sales and marketing costs
|
|
|
(4,679)
|
|
|
—
|
|
|
(4,679)
|
|
Research and development
|
|
|
—
|
|
|
(15,117)
|
|
|
(15,117)
|
|
General and administrative
|
|
|
(953)
|
|
|
(9,887)
|
|
|
(10,840)
|
|
Other expense
|
|
|
(207)
|
|
|
(2,333)
|
|
|
(2,540)
|
|
Segment income (loss)
|
|
$
|
2,297
|
|
$
|
(26,365)
|
|
$
|
(24,068)
|
|
Segment assets
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net
|
|
|
7,022
|
|
|
—
|
|
|
7,022
|
|
Tangible assets
|
|
|
23,550
|
|
|
198,187
|
|
|
221,737
|
|
Total segment assets
|
|
$
|
30,572
|
|
$
|
198,187
|
|
$
|
228,759
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
($ in thousands)
|
|
Products
|
|
Product
|
|
|
|
|
Three Months Ended March 31, 2019
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net revenue
|
|
$
|
6,125
|
|
$
|
352
|
|
$
|
6,477
|
|
Direct cost of goods
|
|
|
(1,884)
|
|
|
—
|
|
|
(1,884)
|
|
Sales and marketing costs
|
|
|
(3,493)
|
|
|
—
|
|
|
(3,493)
|
|
Research and development
|
|
|
—
|
|
|
(23,723)
|
|
|
(23,723)
|
|
General and administrative
|
|
|
(387)
|
|
|
(9,598)
|
|
|
(9,985)
|
|
Other expense
|
|
|
—
|
|
|
16,353
|
|
|
16,353
|
|
Segment income (loss)
|
|
$
|
361
|
|
$
|
(16,616)
|
|
$
|
(16,255)
|
|
Segment assets
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net
|
|
|
1,183
|
|
|
—
|
|
|
1,183
|
|
Tangible assets
|
|
|
9,896
|
|
|
189,459
|
|
|
199,355
|
|
Total segment assets
|
|
$
|
11,079
|
|
$
|
189,459
|
|
$
|
200,538
|
|